AZN

1 Day 1D

5 Days 5D

1 Month 1M

6 Months 6M

YTD YTD

1 Year 1Y

5 Years 5Y

About Astrazeneca plc - ADR

CEO
Pascal Soriot
Employees
76100
Headquarters

1 Francis Crick Avenue
Cambridge, Cambridgeshire CB2 0AA
Phone: 11442073045000
https://www.astrazeneca.com/home

News

Vela Technologies Backs Conduit’s AstraZeneca Deal
Aug 09, 2024 10:48am

Vela Technologies (GB:VELA) has released an update. Vela Technologies, an early-stage tech investment firm, has announced their stake in Conduit Ph…


Source:TipRanks
Conduit Pharmaceuticals and AstraZeneca to Partner on Multiple Assets to Advance Potential First-in-Class Treatments
Aug 09, 2024 00:41am

Conduit Pharmaceuticals Inc. announced … myeloperoxidase inhibitor (MPO). AstraZeneca had progressed AZD1656 and … and AZD5904 from AstraZeneca to Conduit. AstraZeneca has been granted … special offers from American Pharmaceutical Review – all delivered right …


Source:EIN News Pharmaceuticals
AstraZeneca PLC (AZN): Should You Invest in This GLP-1 and Weight Loss Stock Right Now?
Aug 09, 2024 00:23am

We recently compiled a list of the 10 Best GLP-1 and Weight Loss Stocks to Buy Now. In this article, we are going to take a look at where AstraZeneca PLC (NASDAQ:AZN) stands against the other GLP-1 and weight loss stocks. According to WHO, more than one billion people worldwide are obese, including 650 million adults, […]


Source:Insider Monkey
Conduit Pharma Acquires Exclusive Rights to AstraZeneca’s Promising Drug Candidates
Aug 08, 2024 14:32pm

… . 08.08.24 Conduit Pharmaceuticals Inc., which recently opened … into an agreement with AstraZeneca to exclusively license rights … of future sublicensing revenues. AstraZeneca will provide pre-clinical and … . Given the data from AstraZeneca ’s clinical trials, we …


Source:EIN News Pharmaceuticals
AstraZeneca Q1 Results: Net loss reported at Rs 12 cr
Aug 08, 2024 14:20pm

Total income stood at Rs 396 crore for the June quarter against Rs 303 crore in the year-ago period, AstraZeneca Pharma India said in a regulatory filing


Source:Economic Times India
S&P 500 Gains 1%; US Jobless Claims Fall To 230,000
Aug 08, 2024 13:51pm

U.S. stocks traded higher this morning, with the S&P 500 gaining around 1% on Thursday. The Dow traded up 0.69% to 39,031.86 while the NASDAQ rose 1.33% to 16,411.69. The S&P 500 also rose, gaining, 1.07% to 5,255.11. Leading and Lagging Sectors Information technology shares climbed by 1.6% on Thursday. In trading on Thursday, utilities shares fell by 0.2%. Top Headline U.S. initial jobless claims declined by 17,000 to 230,000 in the week ending August 3, compared to market estimates of 240,000. Equities Trading UP Conduit Pharmaceuticals Inc. (NASDAQ: CDT ) shares shot up 100% to $0.3304 after the company announced it entered into an exclusive license agreement with AstraZeneca to develop AZD1656 and AZD5658. Shares of Comstock Inc. (NASDAQ: Full story available on Benzinga.com


Source:Benzinga
AstraZeneca licensing deal boosts Conduit Pharma
Aug 08, 2024 12:19pm

No summary available.


Source:Seeking Alpha
Conduit Pharmaceuticals Shares Soar In Pre-market, Why?
Aug 08, 2024 12:18pm

Conduit Pharmaceuticals (CDT) has entered into an agreement with AstraZeneca to exclusively license rights to develop AZD1656 and AZD5658, both HK-4 glucokinase activators, and AZD5904, a myeloperoxidase inhibitor. AstraZeneca will grant Conduit an exclusive license to both AZD1656 and AZD5658 for all human indications, as well as an exclusive license to AZD5904 for use in Idiopathic Male Infertility.


Source:RTT News
Why Is Conduit Pharmaceuticals (CDT) Stock Up 123% Today?
Aug 08, 2024 11:57am

Conduit Pharmaceuticals (NASDAQ: CDT ) stock is rocketing higher on Thursday after the clinical-stage specialty biopharmaceutical company announced an exclusive license agreement with AstraZeneca (NASDAQ: AZN ). This has Conduit Pharmaceuticals obtaining exclusive rights for three product candidates in development at AstraZeneca. That includes HK-4 glucokinase activators AZD1656 and AZD5658, as well as myeloperoxidase inhibitor AZD5904. Development progress includes AZD1656 and AZD5904 already completing Phase 1 clinical trials. Conduit Pharmaceuticals also notes that it intends to launch Phase 2 clinical trials for AZD1656 and AZD5658 this year. It intends to test their effectiveness as autoimmune disorder treatments. Conduit Pharmaceuticals CEO Dr. David Tapolczay said the following about the deal. “The potential of these assets to become important first-in-class medicines for patients is promising. Given the data from AstraZeneca’s clinical trials, we believe there is a strong rationale to initiate Phase II studies in multiple indications to progress to commercialization of these assets.” CDT Stock Jumps on AZN Agreement News of this license agreement brings with it heavy trading of CDT stock.


Source:InvestorPlace
Conduit Pharmaceuticals Enters into Exclusive License Agreement with AstraZeneca for Multiple Assets to Advance Potential First-in-Class Treatments | CDT Stock News
Aug 08, 2024 10:30am

Conduit Pharmaceuticals secures AstraZeneca assets for autoimmune and infertility treatments. Phase II trials planned for 2024. Promising preclinical data, but potential shareholder dilution looms. Explore the deal''s impact on drug development.


Source:Stock Titan